Free Trial

ArriVent BioPharma (AVBP) News Today

ArriVent BioPharma logo
$20.40 -0.23 (-1.11%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$20.40 0.00 (0.00%)
As of 05/23/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AVBP Latest News

ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 4.5% - Time to Sell?
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.5% - Here's What Happened
ArriVent BioPharma, Inc. stock logo
Rafferty Asset Management LLC Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Rafferty Asset Management LLC raised its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 186.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,299 shares of the company's stock after buying an addition
ArriVent BioPharma, Inc. stock logo
Suvretta Capital Management LLC Acquires 400,838 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Suvretta Capital Management LLC increased its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 21.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,246,000 shares of the company's stock after purchasing an addition
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings
B. Riley Lifts Earnings Estimates for ArriVent BioPharma
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results, Misses Estimates By $1.24 EPS
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($1.24).
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by Octagon Capital Advisors LP
Octagon Capital Advisors LP grew its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,059,387 shares of the company's stock after acquiring an additional 83,000 share
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 6.7% - Here's Why
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.7% - Should You Sell?
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Buy" by Analysts
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong bu
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (AVBP) to Release Earnings on Wednesday
ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-arrivent-biopharma-inc-stock/)
ArriVent BioPharma, Inc. stock logo
Barclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Barclays PLC increased its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 28.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 53,499 shares of the company's stock after purchasing an additional 11,977 shares during the period
ArriVent BioPharma, Inc. stock logo
Invesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Invesco Ltd. purchased a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 15,339 shares of the company's stock, valued at approximately $
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - Here's Why
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - Time to Sell?
ArriVent BioPharma, Inc. stock logo
Novo Holdings A S Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Novo Holdings A S boosted its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,520,627 shares of the company's stock after acquiring an additional 15,3
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 5,360,000 shares, a growth of 31.7% from the March 31st total of 4,070,000 shares. Based on an average trading volume of 203,000 shares, the short-interest ratio is currently 26.4 days. Currently, 27.6% of the shares of the stock are sold short.
ArriVent BioPharma appoints new board member
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 4.9% - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Trading 4.9% Higher - Time to Buy?
ArriVent BioPharma, Inc. stock logo
41,921 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Wellington Management Group LLP
Wellington Management Group LLP purchased a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 41,921 shares of the company's stock, valued at approximately $1,
ArriVent BioPharma, Inc. stock logo
Vanguard Group Inc. Has $37.76 Million Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Vanguard Group Inc. raised its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 5.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,417,291 shares of the company's stock after buying an additional 71,
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Buy" by Brokerages
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the compa
ArriVent Biopharma management to meet with Oppenheimer
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week Low - What's Next?
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month Low - Time to Sell?
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Should You Buy?
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - What's Next?
ArriVent BioPharma, Inc. stock logo
Swiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Swiss National Bank purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 26,400 shares of the company's stock, valued at approximately $703
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 2.2% - Here's Why
ArriVent BioPharma (NASDAQ:AVBP) Trading 2.2% Higher - Time to Buy?
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% - Time to Sell?
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.7% - Should You Sell?
ArriVent BioPharma, Inc. stock logo
Intech Investment Management LLC Acquires Shares of 14,798 ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Intech Investment Management LLC purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,798 shares of the company's stock, valued at appr
ArriVent BioPharma, Inc. stock logo
Brokers Offer Predictions for AVBP Q1 Earnings
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.70) per share for the q
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Raised to Strong-Buy at B. Riley
B. Riley raised shares of ArriVent BioPharma to a "strong-buy" rating in a research report on Wednesday.
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Still a Buy?
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Time to Buy?
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at B. Riley
B. Riley initiated coverage on shares of ArriVent BioPharma in a research note on Thursday. They set a "buy" rating and a $37.00 target price for the company.
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of "Buy" from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have been assigned a consensus rating of "Buy" from the five ratings firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year ta
ArriVent Biopharma initiated with a Buy at B. Riley
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday
ArriVent BioPharma (NASDAQ:AVBP) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.
ArriVent BioPharma, Inc. stock logo
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.5% - Should You Sell?
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 3.5% - Time to Sell?
ArriVent BioPharma appoints PwC as new auditor
Get ArriVent BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.

AVBP Media Mentions By Week

AVBP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVBP
News Sentiment

0.48

0.75

Average
Medical
News Sentiment

AVBP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVBP Articles
This Week

6

2

AVBP Articles
Average Week

Get ArriVent BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AVBP) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners